---
title: "FDA approves Rasonque for pancreatic cancer, doubling survival time"
publication: "MediaBias News"
url: "https://mediabias.news/health/fda-approves-rasonque-for-pancreatic-cancer-doubling-survival-time"
api: "https://mediabias.news/api/v1/stories/fda-approves-rasonque-for-pancreatic-cancer-doubling-survival-time"
markdown: "https://mediabias.news/health/fda-approves-rasonque-for-pancreatic-cancer-doubling-survival-time.md"
audio: "https://mediabias.news/api/audio/fda-approves-rasonque-for-pancreatic-cancer-doubling-survival-time"
category: "Health"
area: "United States"
published: "2026-08-26T16:46:08.248Z"
source_reported: "2026-08-26T16:32:13.943Z"
updated: "2026-08-26T18:00:27.751Z"
trust_score: 60
critic_score: 65
hype_score: 45
assessment_type: "coverage-and-source-reporting-analysis"
fact_check_status: "not-performed"
coverage_measured: "2026-08-26T18:00:10.817781+00:00"
---

# FDA approves Rasonque for pancreatic cancer, doubling survival time

*New drug targets KRAS mutations, offering a more effective treatment for a deadly disease.*

**Scores for the source reporting** (0-100, assessing the original journalism this article was written from, not this write-up): 

- Trust 60 of 100, higher is better. Two full reports and 23 digests corroborate the FDA approval of daraxonrasib for pancreatic cancer.
- Craft 65 of 100, higher is better. Two full reports and multiple digests provide details on the drug's approval, survival rates, and mechanism.
- Hype 45 of 100, lower is better. Headlines use terms like 'landmark' and 'groundbreaking' but the body of the reports is more measured.

Scored by MediaBias News; method at https://mediabias.news/methodology.

**The short version**

- The U.S. Food and Drug Administration (FDA) approved daraxonrasib, sold as Rasonque, for metastatic pancreatic cancer.
- Patients taking daraxonrasib lived a median of 13.2 months in a study, compared to 6.7 months for those on chemotherapy.
- The drug targets KRAS mutations, a key driver of pancreatic cancer growth, previously considered difficult to treat.
- The FDA approved the drug more than six months ahead of its target date.

The U.S. Food and Drug Administration (FDA) has approved a new drug, daraxonrasib, marketed as Rasonque, for adults with metastatic pancreatic cancer who have already undergone prior treatment or cannot receive combination chemotherapy. Pancreatic cancer is one of the deadliest forms of cancer, with an estimated 67,000 new cases and over 52,000 deaths annually in the U.S. The drug targets mutated proteins in the RAS gene family, specifically KRAS mutations, which are known to fuel pancreatic cancer growth and were previously considered difficult to target with medication.

In a study involving 500 patients, those who received daraxonrasib lived for a median of 13.2 months. This is nearly double the median survival time of 6.7 months for patients receiving standard chemotherapy. The FDA granted approval more than six months ahead of its target date. Dr. Pashtoon Kasi of City of Hope Orange County described the drug as "the best option we've ever had" for patients, while acknowledging it is not a cure.

## Disagreement on drug's potential

While the FDA's acting commissioner, Kyle Diamantas, stated it is the agency's "fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible," the reports do not universally describe the drug as a breakthrough. Some digests refer to it as "groundbreaking" or "landmark," while others, such as The Washington Post, quote the headline "FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives." However, the full report from CTV News includes a quote from Dr. Kasi stating, "This is not a cure, it’s one more option for these patients."

## What the coverage left out

None of the right-rated digests mention the specific median survival times reported in the study (13.2 months for daraxonrasib versus 6.7 months for chemotherapy). The full reports from CTV News and CNBC, as well as digests from multiple centre and left-rated outlets, included these figures.

## Who covered it

Shares of the 64 covering outlets with a published leaning rating:

- Left: 20% (13)
- Centre: 72% (46)
- Right: 8% (5)

3 of 67 covering outlets carried no usable leaning rating and were excluded from those percentages. Coverage measured 2026-08-26T18:00:10.817781+00:00.

**Coverage watch:** developing. Checked 8 times; 1 check found a material change. Most recently checked 2026-08-26T18:45:12.209Z.

## How the sides framed it

### Left

- Reports from outlets rated left led on the FDA's approval of daraxonrasib, branded as Rasonque, for metastatic pancreatic cancer. These reports highlighted that the drug nearly doubled average survival times in trials. They noted the drug targets mutated proteins in the RAS gene family, specifically KRAS mutations, which fuel pancreatic cancer growth. Several left-rated outlets used phrases such as "landmark pancreatic cancer drug" in their headlines and descriptions, as seen in digests from The Record, The Seattle Times, The Independent, and The Independent (US). Scientific American's digest described the approval as "heralding a new era for an intractable disease."

### Centre

- The U.S. Food and Drug Administration approved a new drug for pancreatic cancer on Wednesday. The drug, daraxonrasib, targets a mutated protein that fuels tumor growth. CTV News reported that patients taking the drug nearly doubled their survival time in a study.
- The drug, sold under the brand name Rasonque, is for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy. Revolution Medicines developed the pill, which received expedited approval. CTV News noted fewer severe side effects compared to chemotherapy.
- CTV News quoted Dr. Pashtoon Kasi, who called the drug "the best option we've ever had" for patients, while acknowledging it is not a cure. The drug targets KRAS mutations, a driver of pancreatic cancer previously considered "undruggable." STAT reported the approval is expected to usher in a new era of treatment.

### Right

- The two reports rated right focused on the FDA's approval of a new pancreatic cancer drug. The digests from VINnews and The Batesville Daily Guard used the headline "FDA approves landmark pancreatic cancer drug that’s shown to improve survival." Both digests stated that U.S. health officials approved a groundbreaking drug offering a more effective treatment for one of the deadliest forms of cancer. The Batesville Daily Guard digest also noted the drug is a "first-of-a-kind pill from Revolution Medicines."

## Factuality profile of the covering outlets

These are published factuality ratings of the outlets, not a verdict on whether this story or its claims are true.

- mixed: 3
- high: 32
- unknown: 3
- veryHigh: 29

## Verification scope

This page compares coverage and scores the source reporting. It is not a ClaimReview verdict on whether the underlying event or claim is true.

## Original reporting this was written from

- [IBTimes UK](https://ibtimes.co.uk/fda-approves-cancer-pill-doubling-survival-pancreatic-cancer-1816478) — The Pill That Just Cut the Deadliest Cancer's Death Risk by 60% Finally Got FDA's Yes
- [Jerusalem Post](https://jpost.com/health-and-wellness/article-906687) — Revolution Medicines gets FDA approval for targeted pancreatic cancer drug
- [KCRA 3](https://kcra.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WLWT](https://wlwt.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WMUR](https://wmur.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WLKY](https://wlky.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [Koco News5](https://koco.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WESH](https://wesh.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WYFF](https://wyff4.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WDSU](https://wdsu.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WTAE](https://wtae.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [KCCI](https://kcci.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WISN](https://wisn.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [KMBC](https://kmbc.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WPTZ](https://mynbc5.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WBAL-TV](https://wbaltv.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WMTW](https://wmtw.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WVTM](https://wvtm13.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [KOAT](https://koat.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WAPT](https://wapt.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WPBF](https://wpbf.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WXII](https://wxii12.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [KSBW](https://ksbw.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WJCL](https://wjcl.com/article/fda-approves-daraxonrasib-pancreatic-cancer-treatment/73533813) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WCVB](https://wcvb.com/article/fda-daraxonrasib-rasonque-revolution-dana-farber/73533505) — FDA approves first-of-a-kind pancreatic cancer drug trialed in Boston
- [Independent Español](https://independentespanol.com/estilo/salud/la-fda-aprueba-revolucionario-farmaco-contra-el-cancer-de-pancreas-que-mejora-la-supervivencia-b3039846.html) — FDA Approves Revolutionary Drug Against Pancreatic Cancer that Improves Survival
- [Oskaloosa Herald](https://oskaloosa.com/news/national_news/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival/article_baa9cd31-793d-5bb3-a557-c87991466a8b.html) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [The Washington Post](https://washingtonpost.com/health/2026/08/26/fda-approves-landmark-pancreatic-cancer-drug-daraxonrasib) — FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
- [Jornal Expresso](https://expresso.pt/sociedade/saude/2026-08-26-tratamento-revolucionario-para-o-cancro-do-pancreas-aprovado-nos-estados-unidos-ce2bd42c) — Revolutionary Treatment for Pancreatic Cancer Approved in the United States
- [Investor's Business Daily](https://investors.com/news/technology/revolution-medicines-pancreatic-cancer-treatment-approved) — FDA Approves First-Of-Its-Kind Pancreatic Cancer Drug
- [CTV News](https://ctvnews.ca/health/article/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [Moneycontrol](https://moneycontrol.com/news/business/us-fda-approves-revolution-medicines-pancreatic-cancer-drug-rasonque-14016292.html) — US FDA approves Revolution Medicines’ pancreatic cancer drug Rasonque
- [The Record](https://troyrecord.com/2026/08/26/fda-approves-pancreatic-cancer-drug) — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
- [VINnews](https://vinnews.com/2026/08/26/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA Approves Landmark Pancreatic Cancer Drug That’s Shown To Improve Survival
- [Washington Top News](https://wtop.com/national/2026/08/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA approves landmark pancreatic cancer drug that’s shown to improve survival – WTOP News
- [WBAL](https://wbal.com/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA approves landmark pancreatic cancer drug that's shown to impr
- [The Seattle Times](https://seattletimes.com/business/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
- [Winnipeg Free Press](https://winnipegfreepress.com/arts-and-life/life/health/2026/08/26/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [The Toronto Star](https://thestar.com/news/world/united-states/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival/article_0076c3e5-3ee8-50d9-8590-8828ea5366d7.html) — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
- [The Independent](https://independent.co.uk/news/patients-fda-washington-american-cancer-society-cbs-b3039814.html) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WPLG](https://local10.com/news/national/2026/08/26/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [WKMG](https://clickorlando.com/business/2026/08/26/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [The Independent (US)](https://the-independent.com/news/patients-fda-washington-american-cancer-society-cbs-b3039814.html) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [The Batesville Daily Guard](https://guardonline.com/news/national/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival/article_5ca27d7e-9f32-5d2d-b83d-4f4e6e96c35b.html) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [Associated Press News](https://apnews.com/article/pancreatic-cancer-drug-fda-approval-rasonque-03e437bfb8d728ec2a73b142cf8ec2fe) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [Bangor Daily News](https://bangordailynews.com/2026/08/26/nation/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [coasttv.com](https://coasttv.com/news/national/fda-approves-landmark-pancreatic-cancer-drug-thats-shown-to-improve-survival/article_96c5aacf-3c68-5a1e-8a37-6dbdd9a888fe.html) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [CNBC](https://cnbc.com/2026/08/26/revolution-medicines-gets-fda-nod-for-targeted-pancreatic-cancer-drug.html) — Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
- [CNN](https://cnn.com/2026/08/26/health/daraxonrasib-pancreatic-cancer-fda) — Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
- [KMIZ](https://abc17news.com/cnn-health/2026/08/26/revolution-medicines-gets-fda-nod-for-targeted-pancreatic-cancer-drug) — Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
- [KESQ](https://kesq.com/health/cnn-health/2026/08/26/revolution-medicines-gets-fda-nod-for-targeted-pancreatic-cancer-drug) — Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
- [Reuters](https://reuters.com/legal/litigation/revolution-medicines-gets-fda-nod-targeted-pancreatic-cancer-drug-2026-08-26) — Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
- [Bloomberg](https://bloomberg.com/news/articles/2026-08-26/fda-approves-revmed-s-breakthrough-pill-for-pancreatic-cancer) — FDA Approves RevMed’s Breakthrough Pill for Pancreatic Cancer
- [Barron's](https://barrons.com/articles/revolution-medicines-stock-pancreatic-cancer-pill-ccf5b28c) — Revolution Medicines Wins FDA Approval for Cancer Pill. What It Means for the Stock.
- [Wall Street Journal](https://wsj.com/health/pharma/fda-approves-drug-for-pancreatic-cancer-in-incredible-moment-for-deadly-disease-28638f15) — Headline Unavailable
- [BioSpace](https://biospace.com/drug-development/revmed-receives-early-fda-approval-for-groundbreaking-pancreatic-cancer-drug) — RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
- [endpoints.news](https://endpoints.news/fda-approves-revolution-medicines-pancreatic-cancer-drug) — FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy
- [WTVB](https://wtvbam.com/2026/08/26/revolution-medicines-gets-fda-nod-for-targeted-pancreatic-cancer-drug) — Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
- [STAT](https://statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved) — FDA approves new pancreatic cancer drug expected to usher in new era of treatment
- [Market Screener](https://marketscreener.com/news/us-fda-approves-revolution-medicines-pancreatic-cancer-drug-ce7858d9dc80f021) — US FDA approves Revolution Medicines' pancreatic cancer drug
- [WTVR](https://wtvr.com/health/fda-approves-first-of-its-kind-treatment-for-most-common-form-of-pancreatic-cancer) — FDA approves first-of-its-kind treatment for most common form of pancreatic cancer
- [Forbes](https://forbes.com/sites/maryroeloffs/2026/08/26/fda-approves-pancreatic-cancer-drug-that-could-double-survival-time) — FDA Approves Pancreatic Cancer Drug That Could Double Survival Time
- [Scientific American](https://scientificamerican.com/article/u-s-approves-breakthrough-pancreatic-cancer-drug-heralding-a-new-era-for-an-intractable-disease) — U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease
- [Just the News](https://justthenews.com/politics-policy/health/fda-approves-pancreatic-cancer-drug-nearly-doubles-survival-time-over) — FDA approves pancreatic cancer drug that nearly doubles survival time over chemotherapy
- [KATC](https://katc.com/health/fda-approves-first-of-its-kind-treatment-for-most-common-form-of-pancreatic-cancer) — FDA approves first-of-its-kind treatment for most common form of pancreatic cancer
- [NBC Dallas-Fort Worth](https://nbcdfw.com/news/health/fda-approves-pancreatic-cancer-drug-daraxonrasib/4068137) — FDA approves landmark pancreatic cancer drug that's shown to improve survival
- [KPAX](https://kpax.com/health/fda-approves-first-of-its-kind-treatment-for-most-common-form-of-pancreatic-cancer) — FDA approves first-of-its-kind treatment for most common form of pancreatic cancer

## Questions

**What is the new drug approved for pancreatic cancer?**

The U.S. Food and Drug Administration has approved daraxonrasib, which is branded as Rasonque. It is a new treatment option for adults with metastatic pancreatic cancer who have previously received treatment or cannot undergo combination chemotherapy.

**How effective is Rasonque compared to chemotherapy?**

In a study, patients taking Rasonque lived for a median of 13.2 months. This is nearly double the median survival time of 6.7 months for patients who received standard chemotherapy.

**What type of pancreatic cancer does Rasonque treat?**

Rasonque is approved for metastatic pancreatic cancer, which is the most common and deadliest form of the disease. It targets specific mutations in the RAS gene family, particularly KRAS mutations, that drive cancer growth.

---

MediaBias News — https://mediabias.news. Reproduced from https://mediabias.news/health/fda-approves-rasonque-for-pancreatic-cancer-doubling-survival-time. Please cite as: MediaBias News, "FDA approves Rasonque for pancreatic cancer, doubling survival time", https://mediabias.news/health/fda-approves-rasonque-for-pancreatic-cancer-doubling-survival-time